CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
NCT ID: NCT00327418
Last Updated: 2007-05-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
2800 participants
INTERVENTIONAL
1997-01-31
2004-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hypertension (defined as systolic blood pressure 140 mmHg or a diastolic blood pressure 90 mmHg (defined as the disapperance of all sound \[Korotkoff Phase V\] or receiving anti-hypertensive treatment. Blood pressure should be measured after sitting the patient quietly for 3 minutes).
* Retinopathy (defined as any of the following; non-proliferative retinopathy, pre-pre-proliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or history of photocoagulation).
* Microalbuminuria (defined as either, Albumin creatinine ratio \> than = to 2.5 mg/mmol, or Albumin excretion rate on a timed collection \> than = to 20 mcg/min (\> than = to 30 mg/24hrs) on two successive occasions, or a positive micral or other strip test).
* Macroalbuminuria (defined as either; Albustix or other dipstick evidence of gross proteinuria, Albumin creatinine ratio \> than = to 25 mg/mmol; or Albumin excretion rate on a timed collection \> than = 200 mcg/min (\> than = 300 mg/24hrs) on two sucessive occasions).
* Current smoker
Exclusion Criteria
* Any major Coronary event prior to entry into the study
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diabetes UK
OTHER
Department of Health, United Kingdom
OTHER_GOV
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Fosterhill, Aberdeen, United Kingdom
Pfizer Investigational Site
Irvine, Ayrshire, United Kingdom
Pfizer Investigational Site
Midsomer Norton, Bath, United Kingdom
Pfizer Investigational Site
Reading, Berkshire, United Kingdom
Pfizer Investigational Site
Slough, Berkshire, United Kingdom
Pfizer Investigational Site
Maidenhead, Berskhire, United Kingdom
Pfizer Investigational Site
Edgbaston, Birmingham, United Kingdom
Pfizer Investigational Site
Frenchay, Bristol, United Kingdom
Pfizer Investigational Site
Llanishen, Cardiff, United Kingdom
Pfizer Investigational Site
Wrexham, Clwydd, United Kingdom
Pfizer Investigational Site
Bocastle, Cornwall, United Kingdom
Pfizer Investigational Site
Falmouth, Cornwall, United Kingdom
Pfizer Investigational Site
Fowey, Cornwall, United Kingdom
Pfizer Investigational Site
Penzance, CORNWALL, United Kingdom
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Redruth, Cornwall, United Kingdom
Pfizer Investigational Site
Saltash, CORNWALL, United Kingdom
Pfizer Investigational Site
St Austell, Cornwall, United Kingdom
Pfizer Investigational Site
Truro, Cornwall, United Kingdom
Pfizer Investigational Site
Chesterfield, Derbyshire, United Kingdom
Pfizer Investigational Site
Crownhill, Plymouth, DEVON, United Kingdom
Pfizer Investigational Site
Plymouth, Devon, United Kingdom
Pfizer Investigational Site
Plympton, Devon, United Kingdom
Pfizer Investigational Site
Bournemouth, Dorset, United Kingdom
Pfizer Investigational Site
Bournemouth, Dorset, United Kingdom
Pfizer Investigational Site
Epping, Essex, United Kingdom
Pfizer Investigational Site
Southend-on-Sea, Essex, United Kingdom
Pfizer Investigational Site
Langside, Glasgow, United Kingdom
Pfizer Investigational Site
Portsmouth, Hampshire, United Kingdom
Pfizer Investigational Site
Southampton, Hampshire, United Kingdom
Pfizer Investigational Site
Titchfield, Hampshire, United Kingdom
Pfizer Investigational Site
Hemel Hempstead, Hertfordshire, United Kingdom
Pfizer Investigational Site
Watford, Hertfordshire, United Kingdom
Pfizer Investigational Site
Ryde, Isle of Wight, United Kingdom
Pfizer Investigational Site
Gillingham, Kent, United Kingdom
Pfizer Investigational Site
Hildenborough, Kent, United Kingdom
Pfizer Investigational Site
Royal Tunbridge Wells, Kent, United Kingdom
Pfizer Investigational Site
Bolton, Lancashire, United Kingdom
Pfizer Investigational Site
Ormskirk, Lancashire, United Kingdom
Pfizer Investigational Site
Waterloo, Liverpool, United Kingdom
Pfizer Investigational Site
Manchester, M15 6SX, United Kingdom
Pfizer Investigational Site
Ashford, Middlesex, United Kingdom
Pfizer Investigational Site
Southall, Middlesex, United Kingdom
Pfizer Investigational Site
Scunthorpe, North Lincolnshire, United Kingdom
Pfizer Investigational Site
Harrogate, North Yorkshire, United Kingdom
Pfizer Investigational Site
Northallerton, North Yorkshire, United Kingdom
Pfizer Investigational Site
Sutton in Ashfield, Nottinghamshire, United Kingdom
Pfizer Investigational Site
Worksop, Nottinghamshire, United Kingdom
Pfizer Investigational Site
Huthwaite, Nottingham, United Kingdom
Pfizer Investigational Site
Headington, Oxford, United Kingdom
Pfizer Investigational Site
Haverfordwest, Pembrokeshire, United Kingdom
Pfizer Investigational Site
Haverfordwest, Pembrokeshire, United Kingdom
Pfizer Investigational Site
Shrewsbury, Shropshire, United Kingdom
Pfizer Investigational Site
Frome, Somerset, United Kingdom
Pfizer Investigational Site
Weston-super-Mare, Somerset, United Kingdom
Pfizer Investigational Site
Sheffield, South Yorkshire, United Kingdom
Pfizer Investigational Site
Sheffield, South Yorkshire, United Kingdom
Pfizer Investigational Site
Sheffield, South Yorkshire, United Kingdom
Pfizer Investigational Site
Stirling, Stirlingshire, United Kingdom
Pfizer Investigational Site
Carshalton, Surrey, United Kingdom
Pfizer Investigational Site
Epsom, Surrey, United Kingdom
Pfizer Investigational Site
Pontarddulais, Swansea, United Kingdom
Pfizer Investigational Site
Dundee, Tayside, United Kingdom
Pfizer Investigational Site
Dundee, Tayside, United Kingdom
Pfizer Investigational Site
Hetton-Le-Hole, Tyne & Wear, United Kingdom
Pfizer Investigational Site
Gateshead, Tyne and Wear, United Kingdom
Pfizer Investigational Site
Nuneaton, Warwickshire, United Kingdom
Pfizer Investigational Site
Rugby, Warwickshire, United Kingdom
Pfizer Investigational Site
Lyndon, West Bromwich, West Midlands, United Kingdom
Pfizer Investigational Site
Livingston, West Lothian, United Kingdom
Pfizer Investigational Site
Wolverhampton, West Midlands, United Kingdom
Pfizer Investigational Site
Crawley, West Sussex, United Kingdom
Pfizer Investigational Site
Crawley, West Sussex, United Kingdom
Pfizer Investigational Site
Haywards Heath, West Sussex, United Kingdom
Pfizer Investigational Site
Corsham, Wiltshire, United Kingdom
Pfizer Investigational Site
Trowbridge, Wiltshire, United Kingdom
Pfizer Investigational Site
Trowbridge, Wiltshire, United Kingdom
Pfizer Investigational Site
Warminster, Wiltshire, United Kingdom
Pfizer Investigational Site
Westbury, Wiltshire, United Kingdom
Pfizer Investigational Site
York, Yorkshire, United Kingdom
Pfizer Investigational Site
Ayr, , United Kingdom
Pfizer Investigational Site
Ayr, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Belfast, , United Kingdom
Pfizer Investigational Site
Belfast, , United Kingdom
Pfizer Investigational Site
Belfast, , United Kingdom
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
Cambridge, , United Kingdom
Pfizer Investigational Site
Chippenham, Wiltshire, , United Kingdom
Pfizer Investigational Site
Co. Dublin, , United Kingdom
Pfizer Investigational Site
Coventry, , United Kingdom
Pfizer Investigational Site
Derby, , United Kingdom
Pfizer Investigational Site
Dewsbury, , United Kingdom
Pfizer Investigational Site
Dublin, , United Kingdom
Pfizer Investigational Site
Dumfries, , United Kingdom
Pfizer Investigational Site
East Kilbride, , United Kingdom
Pfizer Investigational Site
Edinburgh, , United Kingdom
Pfizer Investigational Site
Edinburgh, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Hartlepool, , United Kingdom
Pfizer Investigational Site
Hertfordshire, , United Kingdom
Pfizer Investigational Site
Hertfordshire, , United Kingdom
Pfizer Investigational Site
Inverness, , United Kingdom
Pfizer Investigational Site
Leicester, , United Kingdom
Pfizer Investigational Site
Liverpool, , United Kingdom
Pfizer Investigational Site
Llantrisant, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Pfizer Investigational Site
Newcastle upon Tyne, , United Kingdom
Pfizer Investigational Site
Nottingham, , United Kingdom
Pfizer Investigational Site
Oldham, , United Kingdom
Pfizer Investigational Site
Paisley, , United Kingdom
Pfizer Investigational Site
Pontefract, , United Kingdom
Pfizer Investigational Site
Southampton, , United Kingdom
Pfizer Investigational Site
Swansea, , United Kingdom
Pfizer Investigational Site
Swansea, , United Kingdom
Pfizer Investigational Site
Wakefield, , United Kingdom
Pfizer Investigational Site
Wigan, , United Kingdom
Pfizer Investigational Site
Wiltshire, , United Kingdom
Pfizer Investigational Site
Wiltshire, , United Kingdom
Pfizer Investigational Site
Wiltshire, , United Kingdom
Pfizer Investigational Site
Wishaw, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA; CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006 Nov;29(11):2378-84. doi: 10.2337/dc06-0872.
Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.
Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL; CARDS, ALLHAT, and ASCOT Investigators. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. Circ Cardiovasc Qual Outcomes. 2016 May;9(3):213-21. doi: 10.1161/CIRCOUTCOMES.115.001980. Epub 2016 May 11.
Soedamah-Muthu SS, Livingstone SJ, Charlton-Menys V, Betteridge DJ, Hitman GA, Neil HA, Bao W, DeMicco DA, Preston GM, Fuller JH, Stehouwer CD, Schalkwijk CG, Durrington PN, Colhoun HM; CARDS Investigators. Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22.
Deshmukh HA, Colhoun HM, Johnson T, McKeigue PM, Betteridge DJ, Durrington PN, Fuller JH, Livingstone S, Charlton-Menys V, Neil A, Poulter N, Sever P, Shields DC, Stanton AV, Chatterjee A, Hyde C, Calle RA, DeMicco DA, Trompet S, Postmus I, Ford I, Jukema JW, Caulfield M, Hitman GA. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res. 2012 May;53(5):1000-1011. doi: 10.1194/jlr.P021113. Epub 2012 Feb 24.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.
Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2009 Feb;52(2):218-25. doi: 10.1007/s00125-008-1176-8. Epub 2008 Oct 30.
Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; Cards Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res. 2008 Sep;5(3):177-83. doi: 10.3132/dvdr.2008.029.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581143
Identifier Type: -
Identifier Source: secondary_id
0981-430-102
Identifier Type: -
Identifier Source: org_study_id